imatinib

(redirected from Gleevac)
Also found in: Dictionary, Wikipedia.

imatinib

 [ĭ-mă´tĭ-nib″]
an inhibitor acting specifically on an abnormal enzyme form that is created by the Philadelphia chromosome abnormality and present in chronic myeloid leukemia. It is used in the treatment of chronic myeloid leukemia during blast crisis, accelerated phase, or chronic phase after failure of interferon-α therapy, administered orally as the mesylate salt.

im·a·tin·ib

(im-ă-tin'ib),
An oral agent important in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors; a specific inhibitor of the Philadelphia reciprocal chromosome translocation-created protein tyrosine kinase enzyme, which works by blocking rapid growth of the mutant clone of tumor cells.

imatinib

/im·at·i·nib/ (ĭ-mă´tĭ-nib″) an antineoplastic used as the mesylate salt in the treatment of chronic myeloid leukemia, inhibiting an abnormal enzyme form constitutively produced in the disease.

imatinib

(ĭ-măt′ə-nĭb)
n.
A tyrosine kinase inhibitor, C29H31N7O, used in its mesylate form to treat certain types of leukemia and various other diseases.

imatinib

[imă′tĭnib′]
an inhibitor acting specifically on an abnormal enzyme form that is created by the Philadelphia chromosome abnormality and present in chronic myeloid leukemia. It is administered orally as the mesylate salt in the treatment of chronic myeloid leukemia during blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy.
References in periodicals archive ?
to safeguard the public interest, and, more importantly in the interpretation of patent legislation as was demonstrated in the Gleevac case.
Another recurrence 18 months later led physicians to try Gleevac therapy, a tyrosine kinase inhibitor, because the tumor was positive for "c-kit" oncogene (CD117).
It is sold under the brand of Glivec worldwide except in the United States, where it is marketed under the name of Gleevac.
After up to 24 months of daily Gleevac therapy 56 patients (38%) had at least a 50% reduction in tumor size; none had a complete response.
Although not approved by the Chinese government for gastric cancer treatment, branded targeted therapies including Bristol-Myers Squibb/Eli Lilly/ImClone Systems/Merck KGaA's Erbitux, Roche's Herceptin and Novartis's Gleevac are currently prescribed off label by Chinese oncologists for gastric cancer treatment.
After up to 24 months of daily Gleevac therapy, 56 patients (38%) had at least a 50% reduction in tumor size; none had a complete response.
Upon his diagnosis, Manny was fortunate enough to be accepted into a clinical trial at Memorial Sloan Kettering (MSK) in New York City for the ground-breaking medical drug STI571 or as it is known today, Gleevac.
The development of successful drugs that target kinases, such as Gleevac and Iressa - which selectively target cancer cells but leave healthy cells unharmed - is being aggressively pursued by pharmaceutical and biotechnology companies, who are looking for quicker, easier solutions for targeting kinase inhibitors.
The development of successful drugs that target kinases, such as Gleevac and Iressa which selectively target cancer cells but leave healthy cells unharmed, is being aggressively pursued by pharmaceutical and biotechnology companies, who are looking for quicker, easier solutions for targeting kinase inhibitors.
In the 1980s, some pharmaceutical companies focused on the development of such drugs, including Gleevac, in order to reduce side effects and increase effectiveness.
The Swiss pharmaceutical company Novartis, which makes an anti-leukemia drug called Gleevac specifically targeting a particular form of cancer, has tested the new law, by seeking to overturn a local ruling that would have prevented Novartis from extending its patent over Gleevac, at a time when Indian generic drug makers want to enter the market.